Shanghai Yingli Pharmaceutical Co., Ltd.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Shanghai Yingli Pharmaceutical Co., Ltd. - overview
Established
2011
Location
Shanghai, -, China
Primary Industry
Pharmaceuticals
About
Established in 2011 and based in Shanghai, China, Shanghai Yingli Pharmaceutical Co. , Ltd. is a medical company that engages in the research and development of small molecule drugs for the treatment of cancer, autoimmune diseases and metabolic disorders. The company also received new drug marketing approval from the National Drug Administration (NMPA) in November 2022 for its self-developed Linperlisib tablets, under the trade name Intarex®.
The company is dedicated to the research and development of clinically unmet needs and focuses on the development of innovative chemical small molecule drugs with proprietary intellectual property rights for the treatment of cancer, autoimmune diseases and metabolic diseases, with its main products being the three types of inhibitors, namely YY-20394, YL-90148, and YL-13027.
Current Investors
Shanghai Zhangjiang Science & Technology Venture Capital, South China Venture Capital, Hongsen Investment
Primary Industry
Pharmaceuticals
Sub Industries
Specialty Pharmaceuticals, Pharmaceutical Research & Development
Website
www.yl-pharma.com
Company Stage
Series A
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.